Details of a
new injection that targets fat cells will be released at the annual meeting of
the European Association
for the Study of Diabetes (EASD) in
Milan, Italy (Sept. 28–Oct. 2). Studies show that the new drug, CBL-514,
reduces levels of subcutaneous and visceral fat. The data also suggest that it
helps limit weight regain after people stop taking GLP-1 receptor agonist drugs
(GLP1-RAs), says Dr. W. Timothy Garvey of the University of Alabama at
Birmingham.
CBL-514 selectively induces apoptosis
(self-destruction) of adipocytes, or fat cells, while leaving other cells
untouched.
In phase 2 clinical trials, the drug reduced the
volume of subcutaneous adipose tissue—the layer of fat that lies just beneath
the skin and can be "pinched"—with 69.6% of treated participants
achieving a reduction of at least 150 mL at the eight-week follow-up, compared
with 0% of those receiving a placebo.
In preclinical studies (animal models), it reduced
weight and levels of subcutaneous and visceral adipose tissue (VAT). Visceral
fat is hidden deep within the abdomen, wrapped around the internal organs. It
is very metabolically active and a key driver of insulin resistance, type 2
diabetes and cardiometabolic conditions such as heart attacks and strokes.
More weight was lost when the drug was given along
with the GLP1-RA tirzepatide. In addition, rats given CBL-514 and tirzepatide
regained less weight when tirzepatide was stopped than rats given tirzepatide
alone.
The hypothesis is that the reduction in fat cells
limits the amount of fat that can be reaccumulated, slowing weight regain.
While GLP1-RAs are highly effective for weight loss,
many people regain weight after stopping treatment. The hope is that CBL-514 will help people keep weight off—allowing
them to sustain the health benefits of weight loss, such as improvements in
blood pressure, blood sugar and cholesterol, says Garvey. However, research is
needed to prove this.
For the latest analysis, Garvey and Yu-Fang Ling of
the drug's developer, Caliway Biopharmaceuticals, in New Taipei City, Taiwan,
used data on a subgroup of participants from the phase 2 trials (CBL-0204 and
CBL-0205) to assess CBL-514's effect on visceral fat in human subjects. They
focused on trial participants for whom MRI data were available.
The participants (BMI 22–30 kg/m2) (age range 36.4 years to 42.4 years) received injections of up to 600
mg of CBL-514 (n=23) or placebo (n=17) into the lower abdomen every three weeks
for up to 12 weeks. The exact number of injections depended on the thickness of
their abdominal fat.
The number of injections was reduced as the
participant's fat thickness decreased, and injections were stopped when the
thickness reached a low enough level. MRI scans were used to measure visceral adipose tissue at baseline, four weeks after the last treatment and eight to 12 weeks
after the last treatment.
VAT volume was similar in the two groups at baseline:
563.85 ml in the CBL-514 group and 659.81 ml in the placebo group. It then
decreased in those receiving the drug and increased in those given the placebo.
Four weeks after the last treatment, average VAT
volume had decreased by 12.01% from baseline in the CBL-514 group, while it had
increased by 5.68% in the placebo group, representing a between-group
difference of 17.69 percentage points.
At the later follow-up—eight weeks after the last
treatment in CBL-0205 and 12 weeks after the last treatment in CBL-0204—average
VAT volume was 10.45% lower than at baseline in the CBL-514 group, while it had
increased by 11.76% in the placebo group, representing a between-group
difference of 22.21 percentage points.
Other than mostly mild to moderate and transient
injection-site reactions, such as pain, swelling and redness, CBL-514 was
generally well tolerated, with no serious adverse events reported.
The researchers conclude that CBL-514 significantly
reduced abdominal VAT volume compared with placebo—and that the research as a
whole shows that the drug can reduce both visceral and subcutaneous fat.
Garvey says, "We expect that patients will be
pleased by the cosmetic effects, such as the flatter stomach that can come with
subcutaneous fat loss. But it is the reduction in body weight, loss of visceral
fat and the improvements in blood pressure, cholesterol and the like that
should be associated with this that will be important for health."
He adds that liposuction and abdominoplasty only
address subcutaneous fat and are more invasive.
"This is a highly innovative approach to obesity
pharmacotherapy that has produced some remarkable results in early human
trials," says Garvey.
Recruitment for the first of two phase 3 trials is underway. These randomized placebo-controlled studies will evaluate the safety and efficacy of CBL-514 for nonsurgical abdominal fat reduction, with the first results expected at the end of next year.
Source: New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells
No comments:
Post a Comment